Trial Profile
An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2019
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Breast cancer
- Focus Biomarker; Therapeutic Use
- 07 Oct 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 04 Jun 2018 Planned End Date changed from 1 Apr 2018 to 30 Apr 2019.